Skip to Content

Acyclovir Pregnancy and Breastfeeding Warnings

Acyclovir is also known as: Sitavig, Zovirax

Acyclovir Pregnancy Warnings

Animal studies have shown this drug readily crosses the placenta. Teratogenicity was not seen when administered to animal models throughout the period of major organogenesis. From 1984 to 1999, a Pregnancy Registry established by the manufacturer and the Centers for Disease Control and Prevention (CDC) collected data for 749 pregnancies (756 outcomes) and found the rate of birth defects for women exposed to systemic drug during the first trimester of pregnancy approximated that of the general population. However, given the small size of the registry, the data is not sufficient to evaluate the risk for less common defects or to permit reliable or definitive conclusions regarding the safety of this drug during pregnancy. There are no controlled data in human pregnancy. AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans. US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

Benefit should outweigh risk AU TGA pregnancy category: B3 US FDA pregnancy category: B Comments: -This drug has been safely used to treat genital herpes in women in all stages of pregnancy. -Women who acquire genital herpes simplex virus (HSV) during late pregnancy should be managed in consultation with maternal-fetal medicine and infectious-disease specialists. -Suppressive therapy late in pregnancy has been shown to reduce the frequency of cesarean delivery among women with recurrent genital herpes by diminishing the frequency of recurrences at term; such treatment may not protect against transmission to neonates in all cases. -Recommended regimen for HSV suppressive therapy in pregnant women with recurrent genital herpes: 400 mg orally 3 times a day starting at 36 weeks gestation.

See references

Acyclovir Breastfeeding Warnings

Adverse effects in breast-feeding infants associated with exposure to this drug via breast milk have not been reported in the literature. With the highest maternal dosage, the expected infant dose is about 1% of a typical infant dose.

Use caution Excreted into human milk: Yes Comments: This drug has been used without apparent harmful effects

See references

References for pregnancy information

  1. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control "1993 Sexually Transmitted Diseases Treatment Guidelines." MMWR Morb Mortal Wkly Rep 42 (1993): 27-46
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  4. "Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc, Morgantown, WV.
  5. "Product Information. Sitavig (acyclovir)." Innocutis Holdings LLC, Charleston, SC.
  6. CDC. Centers for Disease Control and Prevention "Sexually Transmitted Diseases Treatment Guidelines, 2015. Available from: URL: http://www.cdc.gov/std/tg2015/default.htm." (June 5, 2015):

References for breastfeeding information

  1. "Product Information. Sitavig (acyclovir)." Innocutis Holdings LLC, Charleston, SC.
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
  3. CDC. Centers for Disease Control and Prevention "Sexually Transmitted Diseases Treatment Guidelines, 2015. Available from: URL: http://www.cdc.gov/std/tg2015/default.htm." (June 5, 2015):
  4. "Product Information. Acyclovir (acyclovir)." West-Ward Pharmaceuticals Corporation (previously Roxane Laboratories Inc), Columbus, OH.
  5. "Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc, Morgantown, WV.
  6. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  7. Cerner Multum, Inc. "Australian Product Information." O 0

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide